Shire earnings rise on strong Vyvanse demand

Strong demand for hyperactivity treatment Vyvanse helped lift first-quarter earnings 12 percent at Shire, the London-listed drugmaker that is buying U.S. rare diseases firm Baxalta for $32 billion. Quarterly ...